Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 85 OC10.4 | DOI: 10.1530/endoabs.85.OC10.4

BSPED2022 Oral Communications Oral Communications 10 (6 abstracts)

Increasing patient adherence and reducing drug wastage: impact of a personalised patient support programme integrated with a digital connect ecosystem

Anne Marie Larkin 1 , Rose Morrissey 2 , Gurpreet Kaur 3 , Kate Morgan 4 & Ana Rita Batista 4

1Temperature Controlled Pharmaceuticals Ltd. Trading as TCP Homecare, Dublin, Ireland; 2Cork University Hospital, Cork, Ireland; 3Children’s Health Ireland at Crumlin, Dublin, Ireland; 4Merck Serono Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, Feltham, United Kingdom

Background: For chronic non–life-threatening conditions such as growth hormone deficiency, adherence to treatment can be difficult to maintain at a high level especially when the benefits are not immediately apparent.1 Here, we briefly explore some of the components within an e-health ecosystem that aims at personalizing treatment and improving adherence among patients receiving recombinant human growth hormone (r hGH; somatropin, Merck Healthcare KGaA, Darmstadt, Germany)

Objective: To better understand the impact of a personalised patient support programme (MySupport2) embedded in a digitally connected ecosystem (Easypod® connect – EPC Next) for patient adherence and drug wastage, aggregated pseudoanonymised data (from January 2019 to December 2020) was analysed (n=73). In addition, three case studies were observed at baseline reflecting patients with low, medium, and high adherence, assessing also the effect of low adherence on drug wastage.3

Results: As a result of a combined approach of PSP interventions based on utilisation and integration of the EPC system along with close collaboration with clinical endocrinology teams, the average patient adherence to r hGH treatment over the course of 2 years was 83% (n=73). Focusing on 3 case studies, adherence was found to improve with an average supported adherence of 95%. Using the 2nd case study demonstrating medium adherence as an example, the cost of drug wastage reduced from C–178.71 to C–12.77 over one calendar month.3

Conclusion: With the combined support provided by the clinical teams, the MySupport PSP and the adherence monitoring capabilities of the EPC platform, patient adherence and treatment optimisation appeared to be positively impacted. EPC Next highlights when adherence support is required and provides a better measure for the success of the interventions provided by clinical and PSP teams to support dose adjustment decisions, improve adherence to treatment, and reduce drug wastage.

Volume 85

49th Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Belfast, Ireland
02 Nov 2022 - 04 Nov 2022

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.